XML 58 R47.htm IDEA: XBRL DOCUMENT v3.21.2
Acquisition of Tetraphase Pharmaceuticals, Inc. Additional Information (Details) - USD ($)
3 Months Ended 6 Months Ended
Jul. 28, 2020
Jun. 30, 2021
Jun. 30, 2021
Business Acquisition [Line Items]      
Inventory fair value step up adjustment     $ 850,000
Tetraphase Pharmaceuticals, Inc.      
Business Acquisition [Line Items]      
Business acquisition, date of acquisition agreement Jun. 24, 2020    
Upfront cash for acquisition $ 42,990,000    
Future cash payments 16,000,000    
Additional aggregate payments 16,000,000    
Business acquisition, description     The holders of the CVRs are entitled to receive potential future cash payments of up to $16 million in the aggregate upon the achievement of certain net sales of XERAVA in the U.S. as follows: (i) $2.5 million if 2021 XERAVA U.S. net sales are at least $20 million; (ii) $4.5 million if XERAVA U.S. net sales are at least $35 million during any calendar year ending on or prior to December 31, 2024; and (iii) $9 million if XERAVA U.S. net sales are at least $55 million during any calendar year ending on or prior to December 31, 2024.
Estimated fair value of assets acquired 54,700,000    
Estimated fair value of liabilities assumed 9,100,000    
Gail (loss) recorded in other (expense) income resulting from the change in fair value of CVRs   $ 100,000 $ (400,000)
Inventory fair value step up adjustment $ 3,300,000    
Weighted-average Years 10 years    
Tetraphase Pharmaceuticals, Inc. | Cost of Product Sales      
Business Acquisition [Line Items]      
Inventory fair value step up adjustment   $ 0 $ 900,000
Agreement 1 | Tetraphase Pharmaceuticals, Inc.      
Business Acquisition [Line Items]      
Proceeds from businesses and interest in affiliates $ 2,500,000    
Net sales from related parties 20,000,000    
Agreement 2 | Tetraphase Pharmaceuticals, Inc.      
Business Acquisition [Line Items]      
Proceeds from businesses and interest in affiliates 4,500,000    
Net sales from related parties 35,000,000    
Agreement 3 | Tetraphase Pharmaceuticals, Inc.      
Business Acquisition [Line Items]      
Proceeds from businesses and interest in affiliates 9,000,000    
Net sales from related parties $ 55,000,000